Compare Illumina, Inc. (ILMN) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? Illumina, Inc. trades at $192.36 (market cap $27.94B), while Charles Schwab Corporation Common Stock trades at $100.04 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 6.4× Illumina, Inc.'s market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SCHW | |
|---|---|---|
Market Cap | $27.94B | $178.33B |
Sector | Health | Financials |
52-Week High | $194.33 | $107.21 |
52-Week Low | $91.00 | $85.35 |
Enterprise Value | $29.33B | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.53, up 3.15% today, with bullish technical signals and strong fundamental recovery. The stock shows robust profitability with a 19.42% net margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and new executive appointments, reinforcing growth prospects in genomics.
Outlook remains positive driven by sequencing demand and cost control, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is Buy with a $178 target, though the current price exceeds this, suggesting cautious optimism amid execution risks.
Charles Schwab (SCHW) trades at $99.96, down 1.58% on the day, amid strong fundamentals including a 37.99% net income margin and 21.79% ROE. The stock exhibits a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.53 estimated, driven by record revenue and client asset growth. Analyst consensus is bullish with a $120 price target, reflecting 20% upside potential.
Outlook remains positive given consistent earnings beats and robust cash flow, though risks include interest rate sensitivity and competitive pressures. The stock's current valuation at a P/E of 20.39 appears reasonable relative to growth, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
